Avidity Biosciences Stock Revenue
| RNA Stock | USD 43.25 0.69 1.62% |
Avidity Biosciences fundamentals help investors to digest information that contributes to Avidity Biosciences' financial success or failures. It also enables traders to predict the movement of Avidity Stock. The fundamental analysis module provides a way to measure Avidity Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Avidity Biosciences stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 9.6 M | 6.4 M |
Avidity | Revenue |
Avidity Biosciences Company Revenue Analysis
Avidity Biosciences' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Avidity Biosciences Revenue | 9.56 M |
Most of Avidity Biosciences' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Avidity Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Avidity
Projected quarterly revenue analysis of Avidity Biosciences provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Avidity Biosciences match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Avidity Biosciences' stock price.
Avidity Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Avidity Biosciences is extremely important. It helps to project a fair market value of Avidity Stock properly, considering its historical fundamentals such as Revenue. Since Avidity Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Avidity Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Avidity Biosciences' interrelated accounts and indicators.
| 0.17 | 0.98 | 0.81 | 0.22 | -0.1 | ||
| 0.17 | 0.2 | 0.31 | 0.25 | 0.04 | ||
| 0.98 | 0.2 | 0.71 | 0.19 | -0.12 | ||
| 0.81 | 0.31 | 0.71 | 0.55 | 0.15 | ||
| 0.22 | 0.25 | 0.19 | 0.55 | 0.77 | ||
| -0.1 | 0.04 | -0.12 | 0.15 | 0.77 |
Click cells to compare fundamentals
Avidity Revenue Historical Pattern
Today, most investors in Avidity Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Avidity Biosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Avidity Biosciences revenue as a starting point in their analysis.
Avidity Biosciences Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Avidity Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Avidity Biosciences reported 9.56 M of revenue. This is 99.87% lower than that of the Biotechnology sector and 98.71% lower than that of the Health Care industry. The revenue for all United States stocks is 99.9% higher than that of the company.
Avidity Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Avidity Biosciences' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Avidity Biosciences could also be used in its relative valuation, which is a method of valuing Avidity Biosciences by comparing valuation metrics of similar companies.Avidity Biosciences is currently under evaluation in revenue category among its peers.
Avidity Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Avidity Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Avidity Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Avidity Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Avidity Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Avidity Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Avidity Biosciences' value.| Shares | State Street Corp | 2024-06-30 | 3.3 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.5 M | Geode Capital Management, Llc | 2024-06-30 | 2.3 M | Casdin Capital, Llc | 2024-09-30 | 2.1 M | Artisan Partners Limited Partnership | 2024-06-30 | 1.9 M | Boxer Capital Llc | 2024-09-30 | 1.7 M | Nuveen Asset Management, Llc | 2024-06-30 | 1.2 M | Polar Capital Holdings Plc | 2024-06-30 | 1.1 M | Charles Schwab Investment Management Inc | 2024-09-30 | 990.2 K | Fmr Inc | 2024-09-30 | 16.8 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 10.9 M |
Avidity Fundamentals
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.18 | ||||
| Operating Margin | (42.01) % | ||||
| Current Valuation | 3.5 B | ||||
| Shares Outstanding | 119.31 M | ||||
| Shares Owned By Insiders | 4.82 % | ||||
| Shares Owned By Institutions | 95.18 % | ||||
| Number Of Shares Shorted | 14.66 M | ||||
| Price To Earning | (12.91) X | ||||
| Price To Book | 3.38 X | ||||
| Price To Sales | 501.91 X | ||||
| Revenue | 9.56 M | ||||
| Gross Profit | (141.18 M) | ||||
| EBITDA | (233.5 M) | ||||
| Net Income | (212.22 M) | ||||
| Cash And Equivalents | 398.22 M | ||||
| Cash Per Share | 7.64 X | ||||
| Total Debt | 9.85 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.00 X | ||||
| Book Value Per Share | 12.64 X | ||||
| Cash Flow From Operations | (119.06 M) | ||||
| Short Ratio | 17.70 X | ||||
| Earnings Per Share | (2.88) X | ||||
| Target Price | 68.55 | ||||
| Number Of Employees | 253 | ||||
| Beta | 0.91 | ||||
| Market Capitalization | 5.08 B | ||||
| Total Asset | 628.55 M | ||||
| Retained Earnings | (570.76 M) | ||||
| Working Capital | 530.63 M | ||||
| Current Asset | 50.65 M | ||||
| Current Liabilities | 16.97 M | ||||
| Net Asset | 628.55 M |
About Avidity Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Avidity Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avidity Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avidity Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Avidity Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avidity Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avidity Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avidity Biosciences Stock:Check out Avidity Biosciences Piotroski F Score and Avidity Biosciences Altman Z Score analysis. For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avidity Biosciences. If investors know Avidity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avidity Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Revenue Per Share 0.103 | Quarterly Revenue Growth (0.17) | Return On Assets (0.18) | Return On Equity (0.28) |
The market value of Avidity Biosciences is measured differently than its book value, which is the value of Avidity that is recorded on the company's balance sheet. Investors also form their own opinion of Avidity Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Avidity Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avidity Biosciences' market value can be influenced by many factors that don't directly affect Avidity Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avidity Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avidity Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avidity Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.